Increased Business Revenue and Return to Profitability

「In terms of revenue, we recorded business revenue of ¥36,700 thousand, down 15.5% year on year, from recurring research support payments and other payments under joint drug-discovery research agreements. Business expenses totaled ¥283,087 thousand, including research and development expenses of ¥132,404 thousand, resulting in an operating loss of ¥246,387 thousand, compared with an operating loss of ¥186,259 thousand in the same period of the previous year. Non-operating income totaled ¥3,138 thousand, including ¥2,213 thousand in interest income from time deposits and other sources, resulting in an ordinary loss of ¥243,248 thousand, compared with an ordinary loss of ¥182,854 thousand in the same period of the previous year. Extraordinary losses included an impairment loss of ¥141,677 thousand on building fixtures, tools, furniture and fixtures that had begun being used during the fiscal year, resulting in an interim net loss of ¥386,617 thousand, compared with an interim net loss of ¥184,448 thousand in the same period of the previous year.」

「Business revenue for the fiscal year was ¥91,140 thousand, down 53.2% from the previous fiscal year. Business expenses were ¥487,888 thousand, including research and development expenses of ¥215,616 thousand, resulting in an operating loss of ¥396,748 thousand, compared with an operating loss of ¥212,851 thousand in the previous fiscal year. The ordinary loss was ¥390,628 thousand, compared with an ordinary loss of ¥233,562 thousand. An impairment loss of ¥31,318 thousand was recorded as an extraordinary loss, resulting in a net loss of ¥425,671 thousand, compared with a net loss of ¥236,442 thousand in the previous fiscal year.」

「Business revenue was ¥91.140 million, down 53.2% year on year. Business expenses totaled ¥487.888 million, including ¥215.616 million in research and development expenses, resulting in an operating loss of ¥396.748 million, compared with an operating loss of ¥212.851 million in the previous fiscal year.」

「In terms of revenue, we recorded business revenue of ¥43,420 thousand, down 62.6% year on year, from recurring research support payments under joint drug-discovery research agreements and occasional milestone revenue. Business expenses were ¥229,679 thousand, including research and development expenses of ¥94,123 thousand, resulting in an operating loss of ¥186,259 thousand, compared with an operating loss of ¥66,731 thousand in the same period of the previous year. The ordinary loss was ¥182,854 thousand, compared with an ordinary loss of ¥88,729 thousand, and the interim net loss was ¥184,448 thousand, compared with an interim net loss of ¥90,154 thousand.」

「Business expenses totaled ¥182,729 thousand, including research and development expenses of ¥70,240 thousand, resulting in an operating loss of ¥66,731 thousand. Non-operating expenses included ¥12,820 thousand in costs associated with listing the company’s shares on the Tokyo Stock Exchange Growth Market and ¥9,351 thousand in share issuance costs associated with a public offering, among others. Consequently, the ordinary loss was ¥88,729 thousand and the interim net loss was ¥90,154 thousand.」

「During the cumulative first-quarter period, business revenue was ¥32,166 thousand due to the recording of research support payments and other revenue from the mRNA-targeted small-molecule drug-discovery business. Business expenses were ¥97,189 thousand, including research and development expenses of ¥33,649 thousand. Consequently, the operating loss was ¥65,022 thousand, the ordinary loss was ¥87,088 thousand due in part to ¥12,820 thousand in expenses related to listing on the Tokyo Stock Exchange Growth Market recorded as non-operating expenses, and the quarterly net loss was ¥87,800 thousand.」

「As a result, business revenue for the fiscal year was ¥360,356 thousand, compared with ¥178,801 thousand in the previous fiscal year, and business expenses were ¥322,733 thousand, including research and development expenses of ¥136,552 thousand, compared with ¥317,711 thousand in the previous fiscal year. Consequently, operating income was ¥37,623 thousand, compared with an operating loss of ¥138,909 thousand in the previous fiscal year; ordinary income was ¥35,898 thousand, compared with an ordinary loss of ¥138,455 thousand; and net income was ¥33,048 thousand, compared with a net loss of ¥141,381 thousand.」